HC Wainwright Reiterates “$2.00” Price Target for RegeneRx Biopharmaceuticals Inc (RGRX)
HC Wainwright set a $2.00 price objective on RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX) in a research report released on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Shares of RegeneRx Biopharmaceuticals (RGRX) opened at 0.28 on Tuesday. RegeneRx Biopharmaceuticals has a one year low of $0.22 and a one year high of $0.40. The stock’s 50 day moving average price is $0.28 and its 200 day moving average price is $0.28. The stock has a market capitalization of $29.93 million and a PE ratio of 25.45.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/hc-wainwright-reiterates-2-00-price-target-for-regenerx-biopharmaceuticals-inc-rgrx/1537580.html.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.